# A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

> **NCT06733935** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nkarta, Inc.** · enrollment: 144 (estimated)

## Conditions studied

- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
- Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

## Interventions

- **DRUG:** NKX019
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06733935
- **Lead sponsor:** Nkarta, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06733935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06733935, "A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06733935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*